# Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers

> **NCT04416568** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 45 (estimated)

## Conditions studied

- Malignant Rhabdoid Tumor
- Rhabdoid Tumor of the Kidney
- Epithelioid Sarcoma
- Chordoma (Poorly Differentiated or De-differentiated)
- Atypical Teratoid/Rhabdoid Tumor
- Other INI1 Negative Tumors (With PI Approval)
- Other SMARCA4-deficient Malignant Tumors (With PI Approval)

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT04416568
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-08-14
- **Primary completion:** 2025-07-17
- **Final completion:** 2026-06
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2025-12-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04416568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04416568, "Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04416568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*